Related Experiment Video
Updated: Jun 8, 2026
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
15.7K
Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step
Chiara Barattini1,2, Angela Volpe2, Daniele Gori2
1Department of Biomolecular Sciences (DISB), University of Urbino Carlo Bo, 61029 Urbino, Italy.
Cells
|May 13, 2025
Summary
Researchers developed nanoparticle-based drug delivery for prostate cancer, conjugating antibodies and cytotoxic payloads. While showing promise, the nanoparticle construct exhibited lower cytotoxicity than free drugs, indicating further research is needed.
Area of Science:
- Oncology
- Nanomedicine
- Bioconjugation
Background:
- Prostate cancer is a prevalent malignancy with limited treatment options.
- Monoclonal antibody (MoAb) therapy, including antibody-drug conjugates (ADCs), shows promise.
- Prostate-specific membrane antigen (PSMA) is a key target for prostate cancer therapy.
Purpose of the Study:
- To develop and evaluate a nanoparticle-based multimodal tool for targeted prostate cancer drug delivery.
- To describe the step-by-step conjugation of antibodies and cytotoxic payloads onto nanoparticles.
- To screen fluorescent PEGylated silica nanoparticles for selective cancer cell targeting and killing.
Main Methods:
- Fabrication of core-shell nanoparticles with conjugated antibodies and monomethyl auristatin E (MMAE).
- Step-by-step conjugation strategy for antibody and payload attachment.
- Comparative analysis of cytotoxicity between nanoparticle-drug conjugate, antibody-MMAE, and free MMAE.
Main Results:
- The nanoparticle-based construct demonstrated lower cytotoxicity compared to free MMAE.
- Receptor-mediated endocytosis may contribute to the observed reduced efficacy.
- Fluorescent PEGylated silica nanoparticles showed potential for selective cancer cell targeting.
Conclusions:
- Nanomedicine offers a powerful alternative for drug delivery systems in cancer therapy.
- Further research is required to optimize drug loading, release kinetics, and manufacturing scalability.
- Long-term stability of nanoparticle-based therapeutics needs comprehensive investigation.
More Related Videos
Related Concept Videos
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...